The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L.
 
Takehito Shukuya
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Pfizer
 
Takeharu Yamanaka
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Merck; MSD; Taiho Pharmaceutical; Takeda
 
Takashi Seto
Speakers' Bureau - AstraZeneca; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Haruko Daga
No Relationships to Disclose
 
Koichi Goto
No Relationships to Disclose
 
Hideo Saka
No Relationships to Disclose
 
Shunichi Sugawara
No Relationships to Disclose
 
Toshiaki Takahashi
Speakers' Bureau - AstraZeneca; Lilly; Ono Pharmaceutical
 
Soichiro Yokota
No Relationships to Disclose
 
Hiroyasu Kaneda
No Relationships to Disclose
 
Tomoya Kawaguchi
No Relationships to Disclose
 
Seisuke Nagase
No Relationships to Disclose
 
Tetsuya Oguri
Research Funding - Chugai Pharma (Inst); Nippon Kayaku (Inst)
 
Yasuo Iwamoto
No Relationships to Disclose
 
Takashi Nishimura
No Relationships to Disclose
 
Yoshihiro Hattori
Honoraria - Chugai Pharma; Novartis; Taiho Pharmaceutical
 
Kazuhiko Nakagawa
Research Funding - Bristol-Myers Squibb (Inst); Sanofi (Inst)
 
Yoichi Nakanishi
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Pfizer
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst)
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma
Consulting or Advisory Role - Boehringer Ingelheim